Skip to content

Study · Randomized controlled trial · n = 14 · 1996

7 results

Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients.

Ciccarelli E, Grottoli S, Razzore P, Gianotti L, Arvat E, Deghenghi R, Camanni G, Ghigo E

Clinical endocrinology1 Jan 1996Cited by 22 (Europe PMC)

PMID8706295 (opens in a new tab)DOI10.1046/j.1365-2265.1996.626446.x (opens in a new tab)PepBankPUB-08706295
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In normal subjects, hexarelin significantly increased PRL levels versus placebo (P < 0.01).

    In plain wordsIn healthy people, hexarelin raised prolactin levels more than placebo.

    Peptide
    Hexarelin
    Outcome
    IncreasePRL increase in normal subjects
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Hexarelin induced a significant increase in PRL levels in NS (median, range, delta peak HEX vs placebo: 150 (-14-402) vs 10 (-34-24) mU/l; delta AUC HEX vs placebo: 7710 (2,100-3 2540) vs 30 (-2,566-2,040) mU min/l, P < 0.01
    2 context sentences
    Summary · context
    Hexarelin (2 micrograms/kg i.v.), a modified derivative of GHRP-6 of the following structure: His-2-Me-D-Trp-Ala-Trp-D-Phe-Lys-NH2, or placebo, was administered in random order on two separate occasions.
    Summary · context
    Eight patients with active acromegaly (ACRO, 6 F and 2 M, mean age 61.7 years, range 56-73), 6 with macroadenomas and 2 without radiological signs of tumour, and 6 female patients with pathological hyperprolactinaemia (HPRL, mean age 31.2 years, range 18-47) 5 with microadenomas and 1 with empty sella, were studied.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In normal subjects, hexarelin increased GH versus placebo (P < 0.01).

    In plain wordsIn healthy people, hexarelin raised growth hormone more than placebo.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH increase in normal subjects
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    than in NS (90.8 (50.6-181) vs 0.8 (-1.2-6.8) mU/l; 6642 (2,004-13,252.6 vs 42 (456-900) mU min/l, P < 0.01
    2 context sentences
    Summary · context
    Hexarelin (2 micrograms/kg i.v.), a modified derivative of GHRP-6 of the following structure: His-2-Me-D-Trp-Ala-Trp-D-Phe-Lys-NH2, or placebo, was administered in random order on two separate occasions.
    Summary · context
    Eight patients with active acromegaly (ACRO, 6 F and 2 M, mean age 61.7 years, range 56-73), 6 with macroadenomas and 2 without radiological signs of tumour, and 6 female patients with pathological hyperprolactinaemia (HPRL, mean age 31.2 years, range 18-47) 5 with microadenomas and 1 with empty sella, were studied.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with active acromegaly, hexarelin significantly increased PRL levels versus placebo (P < 0.02).

    In plain wordsIn people with active acromegaly, hexarelin raised prolactin levels more than placebo.

    Peptide
    Hexarelin
    Outcome
    IncreasePRL increase in acromegaly
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    and in ACRO (190 (-10-496) vs 6 (-100-34) mU/l; 10,170 (-5,310-51,436) vs -82 (-6,030-1,410) mU min/l, P < 0.02
    2 context sentences
    Summary · context
    Hexarelin (2 micrograms/kg i.v.), a modified derivative of GHRP-6 of the following structure: His-2-Me-D-Trp-Ala-Trp-D-Phe-Lys-NH2, or placebo, was administered in random order on two separate occasions.
    Summary · context
    Eight patients with active acromegaly (ACRO, 6 F and 2 M, mean age 61.7 years, range 56-73), 6 with macroadenomas and 2 without radiological signs of tumour, and 6 female patients with pathological hyperprolactinaemia (HPRL, mean age 31.2 years, range 18-47) 5 with microadenomas and 1 with empty sella, were studied.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with active acromegaly, hexarelin increased GH versus placebo (P < 0.02).

    In plain wordsIn people with active acromegaly, hexarelin raised growth hormone more than placebo.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH increase in acromegaly
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    or in ACRO (117.2 (21.2-420.6 vs 3.8 (-2.2-18) mU/l; 6645 (1,554-22,138.6 vs 334.6 (-324-1,065) mU min/l, P < 0.02
    2 context sentences
    Summary · context
    Hexarelin (2 micrograms/kg i.v.), a modified derivative of GHRP-6 of the following structure: His-2-Me-D-Trp-Ala-Trp-D-Phe-Lys-NH2, or placebo, was administered in random order on two separate occasions.
    Summary · context
    Eight patients with active acromegaly (ACRO, 6 F and 2 M, mean age 61.7 years, range 56-73), 6 with macroadenomas and 2 without radiological signs of tumour, and 6 female patients with pathological hyperprolactinaemia (HPRL, mean age 31.2 years, range 18-47) 5 with microadenomas and 1 with empty sella, were studied.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with pathological hyperprolactinaemia, hexarelin did not significantly increase PRL levels versus placebo.

    In plain wordsIn people with pathologically high prolactin, hexarelin did not raise prolactin more than placebo.

    Peptide
    Hexarelin
    Outcome
    No significant changePRL increase in hyperprolactinaemia
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    but not in HPRL (10 (-180-80) vs 50 (-100-240) mU/l; -600 (-16,996-10,140) vs -1,950 (-8,540-14,160) mU min/l).
    2 context sentences
    Summary · context
    Hexarelin (2 micrograms/kg i.v.), a modified derivative of GHRP-6 of the following structure: His-2-Me-D-Trp-Ala-Trp-D-Phe-Lys-NH2, or placebo, was administered in random order on two separate occasions.
    Summary · context
    Eight patients with active acromegaly (ACRO, 6 F and 2 M, mean age 61.7 years, range 56-73), 6 with macroadenomas and 2 without radiological signs of tumour, and 6 female patients with pathological hyperprolactinaemia (HPRL, mean age 31.2 years, range 18-47) 5 with microadenomas and 1 with empty sella, were studied.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with pathological hyperprolactinaemia, hexarelin increased GH versus placebo (P < 0.05).

    In plain wordsIn people with pathologically high prolactin, hexarelin raised growth hormone more than placebo.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH increase in hyperprolactinaemia
    Study

    n = 6

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Hexarelin also induced a lower increase of GH in HPRL (60 (30-82) vs 1.8 (-0.2-2.2) mU/l; 2,853 (1,477.6-4,372.6 vs 91.6 (-160.6-174) mU min/l, P < 0.05
    2 context sentences
    Summary · context
    Hexarelin (2 micrograms/kg i.v.), a modified derivative of GHRP-6 of the following structure: His-2-Me-D-Trp-Ala-Trp-D-Phe-Lys-NH2, or placebo, was administered in random order on two separate occasions.
    Summary · context
    Eight patients with active acromegaly (ACRO, 6 F and 2 M, mean age 61.7 years, range 56-73), 6 with macroadenomas and 2 without radiological signs of tumour, and 6 female patients with pathological hyperprolactinaemia (HPRL, mean age 31.2 years, range 18-47) 5 with microadenomas and 1 with empty sella, were studied.
  7. 07HumanRandomized controlled trialEfficacy outcome

    Hexarelin induced a lower increase of GH in patients with hyperprolactinaemia than in normal subjects or patients with acromegaly.

    In plain wordsHexarelin raised growth hormone less in people with high prolactin than in healthy people or people with acromegaly.

    Peptide
    Hexarelin
    Outcome
    DecreaseGH increase in hyperprolactinaemia versus normal subjects and acromegaly
    Study

    n: not reported in source

    Comparator
    Normal subjects and acromegaly patients
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Hexarelin also induced a lower increase of GH in HPRL (60 (30-82) vs 1.8 (-0.2-2.2) mU/l; 2,853 (1,477.6-4,372.6 vs 91.6 (-160.6-174) mU min/l, P < 0.05) than in NS (90.8 (50.6-181) vs 0.8 (-1.2-6.8) mU/l; 6642 (2,004-13,252.6 vs 42 (456-900) mU min/l, P < 0.01) or in ACRO (117.2 (21.2-420.6 vs 3.8…
    2 context sentences
    Summary · context
    Hexarelin (2 micrograms/kg i.v.), a modified derivative of GHRP-6 of the following structure: His-2-Me-D-Trp-Ala-Trp-D-Phe-Lys-NH2, or placebo, was administered in random order on two separate occasions.
    Summary · context
    Eight patients with active acromegaly (ACRO, 6 F and 2 M, mean age 61.7 years, range 56-73), 6 with macroadenomas and 2 without radiological signs of tumour, and 6 female patients with pathological hyperprolactinaemia (HPRL, mean age 31.2 years, range 18-47) 5 with microadenomas and 1 with empty sella, were studied.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 18Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 15 times, first on 13 Oct 2026, 21:44 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 12:58 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.